{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:43:02Z","timestamp":1793709782964,"version":"4.6.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Meningococcal serogroup B (MenB) is the leading cause of invasive meningococcal disease among US adolescents and young adults, accounting for 62% of cases in 16\u201323-year-olds in 2018. Since 2015, the Advisory Committee on Immunization Practices (ACIP) has recommended vaccination of healthy adolescents against MenB based on shared clinical decision-making (previously called \u201cCategory B\u201d or individual clinical decision-making). However, MenB vaccine coverage and series completion rates remain low. Herein we examine implementation experience of adolescent MenB vaccination in the United States under this nonroutine ACIP recommendation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed was searched for English-language articles published after 2015 examining MenB vaccination implementation in the United States. Studies reporting MenB vaccination awareness, coverage, knowledge of recommendations and implementation barriers or access disparities were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Identified studies provided evidence that ACIP\u2019s MenB vaccination recommendation is poorly understood and prone to misinterpretation by US healthcare providers. Parental awareness of MenB vaccines is low, and racial and socioeconomic disparities exist regarding vaccine receipt. Parents rely on providers to learn about MenB disease risk and benefits of vaccination, with provider recommendations carrying substantial weight in vaccination decisions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Five years of evidence regarding the MenB vaccination implementation experience suggest that the nonstandard recommendation for MenB vaccines is partly responsible for low vaccine coverage. Further, inconsistent implementation of ACIP recommendations could be limiting access to MenB vaccines. Providers need additional support and guidance to implement the shared clinical decision-making recommendation, in turn ensuring equitable access for vaccine-eligible adolescents to enable comprehensive protection against meningococcal disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003033","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T09:09:32Z","timestamp":1611133772000},"page":"269-275","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Implementation Experience With Meningococcal Serogroup B Vaccines in the United States"],"prefix":"10.1097","volume":"40","author":[{"given":"Jaime","family":"Fergie","sequence":"first","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Driscoll Children\u2019s Hospital, Corpus Christi, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Howard","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, Department of Pediatrics, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Development & Scientific Clinical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Medical Development & Scientific Clinical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"2 suppl","key":"R1-20250615","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements.","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/cid\/ciy548","article-title":"Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013.","volume":"68","author":"Mbaeyi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"e20182130","DOI":"10.1542\/peds.2018-2130","article-title":"Meningococcal disease among college-aged young adults: 2014-2016.","volume":"143","author":"Mbaeyi","year":"2019","journal-title":"Pediatrics"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jpids\/piz024","article-title":"US college students are at increased risk for serogroup B meningococcal disease.","volume":"9","author":"Marshall","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R8-20250615","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.acap.2018.04.005","article-title":"Knowledge and attitudes regarding category B ACIP recommendations among primary care providers for children.","volume":"18","author":"Kempe","year":"2018","journal-title":"Acad Pediatr"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2018.","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.vaccine.2018.11.078","article-title":"Parental awareness of meningococcal B vaccines and willingness to vaccinate their teens.","volume":"37","author":"Basta","year":"2019","journal-title":"Vaccine"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1186\/s12889-020-09181-8","article-title":"Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.","volume":"20","author":"Srivastava","year":"2020","journal-title":"BMC Public Health"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.jadohealth.2019.11.284","article-title":"Understanding patient preferences for meningococcal serogroup B vaccines [281].","volume":"66","author":"Johnson","year":"2020","journal-title":"J Adolesc Health"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"e20180344","DOI":"10.1542\/peds.2018-0344","article-title":"Adoption of serogroup B meningococcal vaccine recommendations.","volume":"142","author":"Kempe","year":"2018","journal-title":"Pediatrics"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/21645515.2019.1682845","article-title":"Disparities in healthcare providers\u2019 interpretations and implementations of ACIP\u2019s meningococcal vaccine recommendations.","volume":"16","author":"Huang","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.acap.2018.01.002","article-title":"Patterns of primary care physician visits for US adolescents in 2014: implications for vaccination.","volume":"18","author":"Rand","year":"2018","journal-title":"Acad Pediatr"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"e20163484","DOI":"10.1542\/peds.2016-3484","article-title":"Understanding the category B recommendation for serogroup B meningococcal vaccine.","volume":"139","author":"Marshall","year":"2017","journal-title":"Pediatrics"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1093\/ofid\/ofy210.2113","article-title":"Factors associated with uptake of meningococcus B vaccination after an ACIP category B recommendation [2460].","volume":"5","author":"Watkins","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 5","key":"R27-20250615","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1469-0691.12447","article-title":"Barriers to the vaccination of children and adolescents and possible solutions.","volume":"20","author":"Esposito","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13012-018-0851-5","article-title":"Barriers and facilitators of pediatric shared decision-making: a systematic review.","volume":"14","author":"Boland","year":"2019","journal-title":"Implement Sci"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jama.2019.3785","article-title":"Shared decision making and the importance of time.","volume":"322","author":"Pieterse","year":"2019","journal-title":"JAMA"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"e20181633","DOI":"10.1542\/peds.2018-1633","article-title":"Strength and clarity of vaccine recommendations influence providers\u2019 practice.","volume":"142","author":"Brady","year":"2018","journal-title":"Pediatrics"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice.","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"R36-20250615","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.pec.2015.12.014","article-title":"Expert and patient consensus on a dynamic model for shared decision-making in frail older patients.","volume":"99","author":"van de Pol","year":"2016","journal-title":"Patient Educ Couns"},{"key":"R37-20250615","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0272989X07307270","article-title":"Communicating the uncertainty of harms and benefits of medical interventions.","volume":"27","author":"Politi","year":"2007","journal-title":"Med Decis Making"},{"key":"R40-20250615","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JOP.18.00019","article-title":"Lessons in integrating shared decision-making into cancer care.","volume":"14","author":"Steffensen","year":"2018","journal-title":"J Oncol Pract"},{"key":"R42-20250615","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R43-20250615","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R44-20250615","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1016\/j.vaccine.2016.10.078","article-title":"Vaccine strategies: optimising outcomes.","volume":"34","author":"Hardt","year":"2016","journal-title":"Vaccine"},{"key":"R46-20250615","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1080\/21645515.2015.1029686","article-title":"Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.","volume":"11","author":"Saez-Llorens","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R47-20250615","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/21645515.2018.1457595","article-title":"Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.","volume":"14","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Hum Vaccin Immunother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:02:32Z","timestamp":1750003352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003033"}},"subtitle":["Impact of a Nonroutine Recommendation"],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003033","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}